XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail) - Level 3 - Fair Value, Recurring - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Equity securities–biotechnology industry        
Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]        
Purchases $ 0.0 $ 4.6 $ 0.0 $ 4.6
Equity securities–biotechnology industry        
Fair Value, Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Roll Forward]        
Balance at beginning of period 0.0 38.9 11.0 38.2
Unrealized gain (loss) included in earnings 0.0 (8.2) 20.8 (7.5)
Transfers out of Level 3 0.0 0.0 (31.8) 0.0
Balance at end of period $ 0.0 $ 35.3 $ 0.0 $ 35.3